SG193446A1 - Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen - Google Patents
Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen Download PDFInfo
- Publication number
- SG193446A1 SG193446A1 SG2013069018A SG2013069018A SG193446A1 SG 193446 A1 SG193446 A1 SG 193446A1 SG 2013069018 A SG2013069018 A SG 2013069018A SG 2013069018 A SG2013069018 A SG 2013069018A SG 193446 A1 SG193446 A1 SG 193446A1
- Authority
- SG
- Singapore
- Prior art keywords
- interferon
- week
- dose
- titration
- package
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161452807P | 2011-03-15 | 2011-03-15 | |
| US201161476930P | 2011-04-19 | 2011-04-19 | |
| PCT/US2012/029201 WO2012125809A1 (en) | 2011-03-15 | 2012-03-15 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG193446A1 true SG193446A1 (en) | 2013-10-30 |
Family
ID=46045072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013069018A SG193446A1 (en) | 2011-03-15 | 2012-03-15 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US9198955B2 (https=) |
| EP (1) | EP2686002B1 (https=) |
| JP (2) | JP6279905B2 (https=) |
| KR (1) | KR102050339B1 (https=) |
| CN (1) | CN103702680A (https=) |
| AU (1) | AU2012229104B2 (https=) |
| BR (1) | BR112013023609A8 (https=) |
| CA (1) | CA2846786C (https=) |
| CY (1) | CY1120176T1 (https=) |
| DK (1) | DK2686002T3 (https=) |
| EA (1) | EA028448B1 (https=) |
| ES (1) | ES2666850T3 (https=) |
| HR (1) | HRP20180621T1 (https=) |
| HU (1) | HUE036931T2 (https=) |
| IL (1) | IL228425A (https=) |
| LT (1) | LT2686002T (https=) |
| MX (1) | MX359947B (https=) |
| PL (1) | PL2686002T3 (https=) |
| PT (1) | PT2686002T (https=) |
| RS (1) | RS57175B1 (https=) |
| SG (1) | SG193446A1 (https=) |
| SI (1) | SI2686002T1 (https=) |
| SM (1) | SMT201800221T1 (https=) |
| WO (1) | WO2012125809A1 (https=) |
| ZA (1) | ZA201306933B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2686002B1 (en) * | 2011-03-15 | 2018-01-24 | Biogen Inc. | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
| EP3092305B1 (en) * | 2014-01-09 | 2023-08-02 | Kyushu University, National University Corporation | Method of producing microglial cells |
| US11266344B2 (en) | 2016-09-21 | 2022-03-08 | Samsung Electronics Co., Ltd. | Method for measuring skin condition and electronic device therefor |
| WO2022069250A1 (en) * | 2020-09-30 | 2022-04-07 | Koninklijke Philips N.V. | Methods and systems for performing dose titration |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456748A (en) | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
| DE3273787D1 (en) | 1981-02-04 | 1986-11-20 | Japan Found Cancer | Human interferon-beta gene |
| US4695543A (en) | 1982-03-23 | 1987-09-22 | Bristol-Myers Company | Alpha Interferon GX-1 |
| CA1302320C (en) | 1984-06-11 | 1992-06-02 | Hideo Niwa | Expression of human cromosomal interferon-_ in animal cells |
| US5231176A (en) | 1984-08-27 | 1993-07-27 | Genentech, Inc. | Distinct family DNA encoding of human leukocyte interferons |
| FI90990C (fi) | 1984-12-18 | 1994-04-25 | Boehringer Ingelheim Int | Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi |
| EP0205404B1 (en) | 1985-06-11 | 1992-07-15 | Ciba-Geigy Ag | Hybrid interferons |
| US5641656A (en) | 1993-10-22 | 1997-06-24 | University Of Connecticut | Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them |
| TR199901968T2 (xx) * | 1996-12-24 | 1999-12-21 | Biogen, Inc. | Sabit s�v� interferon form�lleri. |
| JP2001104482A (ja) * | 1999-10-07 | 2001-04-17 | Terumo Corp | 2室型プレフィルドシリンジ |
| EP1605992B1 (en) * | 2003-01-30 | 2018-11-21 | Becton, Dickinson and Company | Holder with safety shield for a drug delivery device |
| JP4988562B2 (ja) * | 2004-06-01 | 2012-08-01 | アレス トレーディング ソシエテ アノニム | 安定化したインターフェロン液体製剤 |
| US20060089593A1 (en) * | 2004-10-26 | 2006-04-27 | Sergio Landau | Needle-free injection device for individual users |
| EP1923085A1 (en) * | 2006-11-17 | 2008-05-21 | Sanofi-Aventis Deutschland GmbH | Dosing and drive mechanism for drug delivery device |
| CA2672284C (en) * | 2006-12-18 | 2014-08-26 | Altus Pharmaceuticals Inc. | Human growth hormone formulations |
| US9044378B2 (en) * | 2007-05-31 | 2015-06-02 | Safety Syringes, Inc. | Anti-needle stick safety device or system for use with drugs requiring reconstitution |
| JP5549048B2 (ja) * | 2007-08-16 | 2014-07-16 | 味の素株式会社 | 薬剤バイアルとプレフィルドシリンジの接続構造 |
| JP2012530721A (ja) * | 2009-06-18 | 2012-12-06 | ワイス・エルエルシー | 小モジュール免疫薬のための凍結乾燥製剤 |
| EP2686002B1 (en) * | 2011-03-15 | 2018-01-24 | Biogen Inc. | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
-
2012
- 2012-03-15 EP EP12719487.6A patent/EP2686002B1/en active Active
- 2012-03-15 HU HUE12719487A patent/HUE036931T2/hu unknown
- 2012-03-15 PT PT127194876T patent/PT2686002T/pt unknown
- 2012-03-15 SG SG2013069018A patent/SG193446A1/en unknown
- 2012-03-15 CN CN201280019863.2A patent/CN103702680A/zh active Pending
- 2012-03-15 EA EA201301024A patent/EA028448B1/ru unknown
- 2012-03-15 JP JP2013558168A patent/JP6279905B2/ja active Active
- 2012-03-15 ES ES12719487.6T patent/ES2666850T3/es active Active
- 2012-03-15 WO PCT/US2012/029201 patent/WO2012125809A1/en not_active Ceased
- 2012-03-15 RS RS20180455A patent/RS57175B1/sr unknown
- 2012-03-15 AU AU2012229104A patent/AU2012229104B2/en active Active
- 2012-03-15 SM SM20180221T patent/SMT201800221T1/it unknown
- 2012-03-15 KR KR1020137027053A patent/KR102050339B1/ko active Active
- 2012-03-15 CA CA2846786A patent/CA2846786C/en active Active
- 2012-03-15 MX MX2013010507A patent/MX359947B/es active IP Right Grant
- 2012-03-15 US US13/421,197 patent/US9198955B2/en active Active
- 2012-03-15 HR HRP20180621TT patent/HRP20180621T1/hr unknown
- 2012-03-15 SI SI201231281T patent/SI2686002T1/en unknown
- 2012-03-15 LT LTEP12719487.6T patent/LT2686002T/lt unknown
- 2012-03-15 DK DK12719487.6T patent/DK2686002T3/en active
- 2012-03-15 BR BR112013023609A patent/BR112013023609A8/pt not_active Application Discontinuation
- 2012-03-15 PL PL12719487T patent/PL2686002T3/pl unknown
-
2013
- 2013-09-12 IL IL228425A patent/IL228425A/en active IP Right Grant
- 2013-09-12 ZA ZA2013/06933A patent/ZA201306933B/en unknown
-
2015
- 2015-11-09 US US14/936,228 patent/US20160101157A1/en not_active Abandoned
-
2017
- 2017-09-05 US US15/695,587 patent/US10500254B2/en active Active
- 2017-09-05 JP JP2017170640A patent/JP6522069B2/ja active Active
-
2018
- 2018-04-23 CY CY20181100424T patent/CY1120176T1/el unknown
-
2019
- 2019-10-22 US US16/660,038 patent/US20200046804A1/en not_active Abandoned
-
2022
- 2022-05-27 US US17/827,282 patent/US20220280610A1/en not_active Abandoned
-
2025
- 2025-05-05 US US19/198,871 patent/US20250276042A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250276042A1 (en) | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen | |
| EP2533634B1 (en) | Neuroprotection in demyelinating diseases | |
| CN102458476A (zh) | 用于治疗多发性硬化症的组合物及方法 | |
| AU776181B2 (en) | Combined treatment of multiple sclerosis | |
| HK1192473B (en) | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen | |
| HK1192473A (en) | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen | |
| NZ712273B2 (en) | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen | |
| NZ616536B2 (en) | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen | |
| CN101180044B (zh) | 用于自身免疫损伤后中枢神经系统神经再生的egf/ghrp-6组合 | |
| EP1471974B1 (en) | Tumor necrosis factor combined with interferon in demyelinating diseases | |
| Johnson | Role of interferons in demyelinating disease | |
| HK1179116B (en) | Neuroprotection in demyelinating diseases |